Pinar Akokay

Pinar Akokay

Auto-generated profile, based on publicly available information

Pinar Akokay

Kavram Vocational School, Department of Histology, İzmir, Türkiye

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 November 2021 in The Anatolian Journal of Cardiology
Verified
Journal Article
Open access
FDFerhat Dindaş
Ferhat Dindaş
HGHüseyin Güngör
Hüseyin Güngör
MEMehmet Ekici
Mehmet Ekici
PAPınar Akokay
Pınar Akokay
FEFüsun Erhan
Füsun Erhan
MYMehmet Birhan Yilmaz
Mehmet Birhan Yilmaz
Doxorubicin (DOX) is a well-known cardiotoxic agent, whereas sacubitril/valsartan (Sac/Val) is an effective treatment option in heart failure. In this study, we aimed to evaluate the effect of Sac/Val on DOX-induced cardiotoxicity in pretreatment mice model. A total of 24 mice were equally classified into 4 groups; control group, DOX (20 mg/kg; fifth day), Sac/Val (80 mg/kg), and Sac/Val+DOX (Sac/Val was given from day one of the study before doxorubicin administration). Electrocardiography parameters, including durations of QRS, ST, QT, PP segment, and QT/PQ index were measured. Total antioxidant status (TAS), total oxidant status (TOS), tumor necrosis factor-α (TNF-α), interleukin 1β (IL-1β), IL-6, NT-proBNP concentrations, and Caspase 3 activity were evaluated. At the end of the 9-day study duration, QRS, ST, QT intervals, QT/PQ index and TAS, TOS, TNF-α, IL-1β, IL-6 levels were significantly higher in the DOX group than in the control group (p<0.001). Moreover, there were significant differences only in the PP interval when comparing the Sac/Val+DOX and control groups (p<0.001). QRS, ST, QT intervals, and QT/PQ index, TAS, TOS, TNF-α, IL-1β, IL-6 levels were significantly lower in the Sac/Val+ DOX group compared with the DOX group (p<0.001). Furthermore, NT-proBNP levels were lower in the Sac/Val+DOX group compared with the DOX group along with less Caspase 3 apoptosis. Sac/Val seems to be cardioprotective against DOX-induced cardiotoxicity in pretreatment mice model. These findings can be attributed to the antiarrhythmic, anti-inflammatory, antioxidant, and antiapoptotic effects of Sac/Val as shown in this study.

18 June 2024 in Food Science & Nutrition
Verified
Journal Article
Open access
NANurten Alan
Nurten Alan
NONazan Tuna Oran
Nazan Tuna Oran
PYPınar Akokay Yılmaz
Pınar Akokay Yılmaz
AÇAslı Çelik
Aslı Çelik
OYOsman Yılmaz
Osman Yılmaz
Intestinal mucositis poses a significant concern associated with cancer therapy. This study aims to investigate the protective and/or healing effect of fig seed oil (FSO) on 5‐fluorouracil (5‐FU)‐induced intestinal mucositis by targeting inflammatory markers and histologic changes in rats. Albino Wistar adult rats were randomly divided into four groups, including three male and three female animals. All the animals in the four groups had a normal standard diet and water throughout the experimental period, which lasted up to 11 days. Rats were administered FSO 0.6 mL (mucositis FSO group) and FSO 0.2 mL (mucositis FSO‐R group) daily throughout the experiment. These two groups and one additional group (mucositis group) were given an intraperitoneal injection of 5‐FU (300 mg/kg) on Day 5 of the experiment. In contrast, the fourth group (Control group) was given an intraperitoneal saline injection on Day 5 of the experiment. FSO treatment ameliorated 5‐FU‐induced intestinal mucositis. On immunohistologic examination, FSO suppressed significantly the activation of NF‐κB and expression of IL‐β and TNF‐α of the harvested intestinal tissue. The reduced dose FSO (mucositis FSO‐R) was as effective as the full dose (mucositis FSO) in suppressing IL‐β and TNF‐α production, but was not as effective as the full dose in suppressing NF‐κB. On light microscopy, FSO attenuated significantly 5‐FU‐induced anomalies, such as the reduction of intestinal villus length and Goblet cell count. The reduced dose FSO (mucositis FSO‐R) was as effective as the full dose (mucositis FSO) in restoring villus length, but was not as effective as the full dose in restoring Goblet cell count. The findings of the study suggest that FSO inhibits 5‐FU‐induced intestinal mucositis via modulation of mucosal inflammation.

3 August 2020 in General Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
PDF file
TGTugra Gencpinar
Tugra Gencpinar
SBSerdar Bayrak
Serdar Bayrak
CBCagatay Bilen
Cagatay Bilen
MKMustafa Barış Kemahlı
Mustafa Barış Kemahlı
PAPinar Akokay
Pinar Akokay
CECenk Erdal
Cenk Erdal

1 July 2023 in Turkish Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Open access
TGTugra Gencpinar
Tugra Gencpinar
CBCagatay Bilen
Cagatay Bilen
MKMustafa Barış Kemahlı
Mustafa Barış Kemahlı
KKKivanc Kacar
Kivanc Kacar
PAPinar Akokay
Pinar Akokay
CECenk Erdal
Cenk Erdal
Background: This study aims to demonstrate the efficacy of rivaroxaban’s pharmacokinetic effects on myocardial mitophagy in rats by inducing apoptosis. Methods: In this double-blind experiment, Wistar albino male rats were randomly divided into three groups for an experimental ischemia model: the sham group (Group 1; n=7), the control group (Group 2; n=7), and the drug group (Group 3; n=7). Rivaroxaban was perorally administered with gavage at 2 mg/ kg/day for 28 days in Group 3. The heart was surgically exposed, and ischemia was achieved by compressing the vessel around the proximal part of the left anterior descending coronary artery for 10 min. The heart tissue was then transected, removed, and morphologically and immunohistochemically examined under a light microscope. Results: Heart sections were immunohistochemically marked with caspase 3, caspase 9, APAF1, and Bcl-2 antibodies. Group 1 was compared to the rivaroxaban-treated group, and the pathways inducing apoptosis was increased (caspase 3, caspase 9, APAF1; p<0.015, p<0.004, and p<0.01, respectively) and Bcl-2, the molecule that inhibits apoptosis, was decreased (p<0.01) in Group 3. Conclusion: The present study provides an evidence that the mitophagy response is less in rivaroxaban-treated rats, showing the protective effect of rivaroxaban against acute ischemia. Rivaroxaban-treated rats may have reduced cell death in cardiomyocytes during myocardial infarction and thus have reduced damage to the heart tissue caused by myocardial infarction.

25 October 2022 in Turkish Journal of Vascular Surgery
Verified
Journal Article
Open access
MKMustafa Barış Kemahlı
Mustafa Barış Kemahlı
TGTugra Gencpinar
Tugra Gencpinar
HDHuseyin Dursun
Huseyin Dursun
CBCagatay Bilen
Cagatay Bilen
PAPinar Akokay
Pinar Akokay
AEAbidin Cenk Erdal
Abidin Cenk Erdal
Aim: Intimal hyperplasia causes vascular occlusion and its optimal treatment is unknown. In this study, we evaluated the effectiveness of Apixaban and Rivaroxaban treatment for preventing intimal hyperplasia in rabbits. Material and Methods: The rabbits (n = 15) were randomly divided into three groups. Reanastomoses are applied to the carotid artery. All groups received 100 U/kg heparin sodium during the operation period. Group A (n = 5) as a control group had no medication. Group B (n = 5) was given Rivaroxaban 3 mg/kg/day. In-group C (n = 5) Apixaban was administered per orally 10 mg/kg. At the end of the treatment on the 28th day, carotid artery specimens were excised and evaluated histologically.Results: Increased intima thickness was observed in the control group than the drug groups (P=0.019, P=0.007). It was found that there was no difference between groups in terms of lumen diameter, lumen area, tunica media area and tunica media thickness. There was difference between groups in terms of caspase 3 or TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling) staining (p<0.05). Conclusion: Apixaban and Rivaroxaban may have protective efficacy against intimal hyperplasia after vascular surgical intervention.

1 January 2025 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
FAFevzi Ayyıldız
Fevzi Ayyıldız
UKUğur Karagöz
Uğur Karagöz
TKTünay Kurtoğlu
Tünay Kurtoğlu
PAPınar Akokay
Pınar Akokay
ÇBÇağatay Bilen
Çağatay Bilen
SUMMARY OBJECTIVE: Despite the longstanding clinical use of low-molecular-weight heparins and their well-characterized mechanisms of action, their effects on mitophagy pathways in acute myocardial ischemia remain incompletely delineated. The aim of this study was to investigate the enoxaparin effect on cardiomyocyte morphology and the immunopositivity of mitophagy-associated Parkin–LC3 proteins in a rat model of acute myocardial ischemia. METHODS: Female Wistar albino rats (median weight: 400 g, minimum: 375 g-maximum: 415 g) were divided into sham (n=7), control (n=7), and treatment (n=7) groups. The control group received subcutaneous 0.9% saline (0.2 mL/kg) twice daily for 28 days, followed by the induction of myocardial ischemia. The treatment group was administered subcutaneous enoxaparin sodium (1 mg/kg) twice daily for the same duration before undergoing myocardial ischemia. Myocardial ischemia was induced by occluding the proximal left anterior descending coronary artery using a 6-0 polypropylene suture for 10 min. Morphometric calculations of cardiomyocytes (cell length and diameter) were performed using light microscopy. Immunohistochemical analysis was performed using anti-Parkin and anti-LC3 antibodies, and immunopositive cells were counted. RESULTS: Statistically significant differences were found between the groups (p<0.001). Post-hoc analysis revealed significant differences between the control and treatment groups based on cell length, cell diameter, Parkin, and LC3 values (p<0.001, p=0.001, p<0.001, and p=0.001, respectively). CONCLUSION: This study demonstrated that enoxaparin preserved cardiomyocyte morphology and reduced the number of Parkin–LC3 immunopositive cells in a model of induced acute ischemic injury in rat myocardium.